More treatment options for rifampicin-resistant tuberculosis: the role of economic evaluation in informing uptake.

Competing Interests: SS reports grant funding from Médecins Sans Frontières paid to her organisation for economic evaluation work on a trial evaluating shortened regimens for multidrug-resistant and rifampicin-resistant tuberculosis; grant funding from the Bill & Melinda Gates Foundation paid to her organisation for tuberculosis modelling and analysis work; and consulting fees from WHO for support in analysis of patient cost surveys. MPS declares no competing interests.